Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 06/05/2011
PIL Glivec 400 mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to MA holder contact details
Updated on 24/01/2011 and displayed until 06/05/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 23/04/2010 and displayed until 24/01/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change due to user-testing of patient information
Updated on 03/06/2009 and displayed until 23/04/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to storage instructions
  • Change to side-effects
Updated on 12/04/2008 and displayed until 03/06/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 01/02/2008 and displayed until 12/04/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to MA holder contact details
Updated on 14/08/2007 and displayed until 01/02/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 17/01/2007 and displayed until 14/08/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to side-effects
  • Change to warnings or special precautions for use
Updated on 28/04/2006 and displayed until 17/01/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 08/09/2005 and displayed until 28/04/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to drug interactions
  • Change to instructions about overdose
Updated on 18/03/2005 and displayed until 08/09/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 15/03/2004 and displayed until 18/03/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   imatinib mesilate